30.09.2022

Flick Gocke Schaumburg advised ArchiMed on its investment in PlasmidFactory

Flick Gocke Schaumburg has advised private equity healthcare specialist ArchiMed on its investment in PlasmidFactory GmbH & Co. KG, a gene and cell therapy specialist, based in Bielefeld/Germany. Founded in 2000, PlasmidFactory is the leading contract manufacturer and service provider for plasmid and minicircle DNA.

PlasmidFactory is the second buy-and-build investment of ArchiMed’s MED Platform II fund.

Advisor ArchiMed: Flick Gocke Schaumburg

Matthias Full; Associate: Anne-Catherine Lorek (both Private Equity/Tax)

Advice on all tax aspects of the transaction including Tax Due Diligence, Structuring, SPA, SHA, and Funds Flow.

With offices in the US and Europe, ArchiMed is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ArchiMed to serve as both a strategic and financial partner to North American and European healthcare businesses. Prioritized areas of focus include Biopharmaceutical Products & Services, Life Science Tools, Medical Devices & Technologies, Diagnostics, Health Technologies & Software and Consumer Health. Over the last twenty years, ArchiMed’s leadership team has directly managed and invested in over eighty small- to large-size healthcare companies globally, representing over €50 billion of combined value. ArchiMed manages more than €5 billion across its various funds.

PlasmidFactory GmbH & Co. KG is a globally active biopharmaceutical company and has a strong customer base in the fields of cancer research, gene and cell therapy, CAR T-cell development, and vaccination. The company develops and manufactures exceptionally high-grade plasmids and minicircles, used to modify cells and produce viral gene therapy vectors like AAV, LV and mRNA for combating everything from viruses like COVID-19 to seemingly intractable diseases like cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDs (including CAR-T cell applications). Plasmids are notably a key component for the production of mRNA COVID-19 vaccines. <<<